Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 8/20 | 0.48 |
| ▸ | MMP3 | P08254 | 7/20 | 0.48 |
| ▸ | MMP7 | P09237 | 6/20 | 0.48 |
| ▸ | MMP1 | P03956 | 5/20 | 0.48 |
| ▸ | MMP9 | P14780 | 5/20 | 0.48 |
| ▸ | MMP13 | P45452 | 5/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MMP14 | P50281 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10420388 | 0.80 | MMP2 (0.58) | CA12CA1CA2CA9MMP2 | |
| SCHEMBL941159 | 0.80 | MMP2 (0.73) | ALDH1A1POLBSMN1; SMN2MMP2MMP3 | |
| SCHEMBL19183052 | 0.77 | KDM1A (0.48) | ALDH1A1POLBSMN1; SMN2CA12CA1 | |
| SCHEMBL506270 | 0.75 | MAPT (0.55) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL6203735 | 0.74 | RECQL (0.66) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL7385583 | 0.73 | ALDH1A1 (0.67) | ALDH1A1POLBSMN1; SMN2CA12CA1 | |
| SCHEMBL4190362 | 0.73 | PTGS2 (0.72) | CA12CA1CA2CA9MMP2 | |
| SCHEMBL455924 | 0.73 | ALDH1A1 (0.69) | ALDH1A1POLBSMN1; SMN2CA12CA1 | |
| SCHEMBL309411 | 0.73 | CA1 (0.66) | ALDH1A1CA12CA1CA2CA9 | |
| Acetone SCHEMBL3433409 | 0.73 | MMP3 (0.58) | ALDH1A1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-7754750-B2 | a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-7625934-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20080306065-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-7427631-B2 | especially as inhibitors of MMP12 | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| EP-1370556-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | EP | disclosed |
| EP-1676846-A2 | Hydantoin derivatives as MMP inhibitors | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040127528-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | US | disclosed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370556-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074767-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | ALDH1A1 612/4885POLB 789/4885SMN1; SMN2 2584/4885 |
| US-20080306065-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | ALDH1A1 612/4885POLB 789/4885SMN1; SMN2 2584/4885 |
| US-20080171882-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | ALDH1A1 612/4885POLB 789/4885SMN1; SMN2 2584/4885 |
| US-20040127528-A1 | Metalloproteinase inhibitors | MMP9, MMP10, MMP3 | ALDH1A1 573/4885POLB 1172/4885SMN1; SMN2 3138/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | ALDH1A1 1250/4885POLB 2347/4885SMN1; SMN2 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.